General Information of Drug (ID: DMR7EF6)

Drug Name
KHK-2866 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMR7EF6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
U3-1565 DMWOE62 Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
ASP0598 DM9QUCH Chronic tympanic membrane perforation AB13 Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proheparin-binding EGF-like growth factor (HBEGF) TT15SL0 HBEGF_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
2 J Clin Oncol 31, 2013 (suppl; abstr 2519).
3 ClinicalTrials.gov (NCT04305184) A Phase 1/2, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of ASP0598 Otic Solution Following Topical Application Into the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP). U.S.National Institutes of Health.